Biogen Extends Gains

Biogen Idec Inc. (BIIB) extended its gains by climbing another $2.03 to close at $47.54. Yesterday, a Food and Drug Administration advisory committee voted unanimously to allow the recalled multiple sclerosis drug Tysabri back on the market. Biogen developed the drug with Elan Corp. (ELN), whose shares edged down 49 cents to close at $15.32.